Biotron Ltd has announced the successful conclusion of their phase IIa HCV trial, with headline data released today. The trial was designed to test safety and efficacy of Biotron’s lead drug, BIT225, an orally administered, first in class drug that is being investigated as a potential platform treatment for viruses including HCV, HIV, Dengue, influenza and HBV.
BIT225 or placebo was dosed for 28 days with interferon and ribavirin (the current standard of care for HCV patients). This early-stage trial has demonstrated a significant reduction in viral load compared to the current standard of care. Patients had an order of magnitude improvement over the current standard of care.
The next step for Biotron is to secure a partnership with one of the major pharmaceutical companies trying to enter this +$3 billion market.
Massively encouraging stuff.
hcv trial success
-
- There are more pages in this discussion • 41 more messages in this thread...
This thread is closed.
You may not reply to this discussion at this time.
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
